NEW PEPTIDE-BASED CANCER VACCINE: PHASE I AND EARLY PHASE II CLINICAL TRIALS FOR CASTRATION-RESISTANT PROSTATE CANCER

被引：0
|
作者：
Noguchi, M. [1 ,2 ]
Suekane, S. [2 ]
Moriya, F. [2 ]
Sasada, T. [3 ]
Yamada, A. [3 ]
Itoh, K. [3 ]
机构：
[1] Kurume Univ, Sch Med, Res Ctr Innovat Canc Therapy, Div Clin Res, Kurume, Fukuoka 830, Japan
[2] Kurume Univ, Sch Med, Dept Urol, Kurume, Fukuoka 830, Japan
[3] Kurume Univ, Sch Med, Dept Immunol & Immunotherapy, Kurume, Fukuoka 830, Japan
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：74 / 74
页数：1
相关论文
共 50 条
  • [21] Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancer
    Nozawa, Masahiro
    Mukai, Hirofumi
    Takahashi, Shunji
    Uemura, Hiroji
    Kosaka, Takeo
    Onozawa, Yusuke
    Miyazaki, Jun
    Suzuki, Kazuhiro
    Okihara, Koji
    Arai, Yoichi
    Kamba, Tomomi
    Kato, Masashi
    Nakai, Yasutomo
    Furuse, Hiroshi
    Kume, Haruki
    Ide, Hisamitsu
    Kitamura, Hiroshi
    Yokomizo, Akira
    Kimura, Takahiro
    Tomita, Yoshihiko
    Ohno, Keiji
    Kakehi, Yoshiyuki
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2015, 20 (05) : 1026 - 1034
  • [22] Synergistic effects of everolimus and bicalutamide in castration-resistant prostate cancer: Results from a phase I/II clinical trial
    Pan, Chong-xian
    Robles, Daniel
    D'Abronzo, Leandro
    Beggs, Ryan E.
    deVere-White, Ralph
    Lara, Primo
    Ghosh, Paramita M.
    CANCER RESEARCH, 2012, 72
  • [23] Disparities in Castration-Resistant Prostate Cancer Trials
    Spratt, Daniel E.
    Osborne, Joseph R.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (10) : 1101 - 1103
  • [24] Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium
    Beer, T. M.
    Smith, D. C.
    Hussain, A.
    Alonso, M.
    Wang, J.
    Giurescu, M.
    Roth, K.
    Wang, Y.
    BRITISH JOURNAL OF CANCER, 2012, 107 (05) : 808 - 813
  • [25] Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium
    T M Beer
    D C Smith
    A Hussain
    M Alonso
    J Wang
    M Giurescu
    K Roth
    Y Wang
    British Journal of Cancer, 2012, 107 : 808 - 813
  • [26] A phase I/II study of enzalutamide in combination with indomethacin in men with castration-resistant prostate cancer (CRPC)
    Leibrandt, Ryan
    Ullah, Ayman Teeham
    Verma, Rashmi
    Gao, Allen
    Lara, Primo N., Jr.
    Pan, Chong-xian
    Parikh, Mamta
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [27] A Phase I-II Study of Docetaxel and Atrasentan in Men with Castration-Resistant Metastatic Prostate Cancer
    Armstrong, Andrew J.
    Creel, Patricia
    Turnbull, James
    Moore, Cassandra
    Jaffe, Tracy A.
    Haley, Sherri
    Petros, William
    Yenser, Sarah
    Gockerman, Jon P.
    Sleep, Darryl
    Hurwitz, Herbert
    George, Daniel J.
    CLINICAL CANCER RESEARCH, 2008, 14 (19) : 6270 - 6276
  • [28] Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer
    Bratt, O.
    Haggman, M.
    Ahlgren, G.
    Nordle, O.
    Bjork, A.
    Damber, J-E
    BRITISH JOURNAL OF CANCER, 2009, 101 (08) : 1233 - 1240
  • [29] Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study
    Petrylak, Daniel P.
    Loriot, Yohann
    Shaffer, David R.
    Braiteh, Fadi
    Powderly, John
    Harshman, Lauren C.
    Conkling, Paul
    Delord, Jean-Pierre
    Gordon, Michael
    Kim, Joseph W.
    Sarkar, Indrani
    Yuen, Kobe
    Kadel, Edward E.
    Mariathasan, Sanjeev
    O'Hear, Carol
    Narayanan, Sujata
    Fasso, Marcella
    Carroll, Susheela
    Powles, Thomas
    CLINICAL CANCER RESEARCH, 2021, 27 (12) : 3360 - 3369
  • [30] Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer
    O Bratt
    M Häggman
    G Ahlgren
    Ö Nordle
    A Björk
    J-E Damber
    British Journal of Cancer, 2009, 101 : 1233 - 1240
12345